WASHINGTON, Jan 10 (Reuters) - Taiwan Semiconductor Manufacturing Co (2330.TW), opens new tab has begun producing advanced four-nanometer chips for U.S. customers in Arizona, Commerce Secretary Gina Raimondo told Reuters, a milestone in the Biden administration's semiconductor efforts.

Approximate $7 billion investment over the next several years to meet AI data center demand

MILPITAS, Calif. — January 7, 2025 — The semiconductor industry is expected to start 18 new fab construction projects in 2025*, according to SEMI's latest quarterly World Fab Forecast report. The new projects include three 200mm and fifteen 300mm facilities, the majority of which are expected to begin operations from 2026 to 2027.

Sales hit highest-ever monthly total in November; worldwide chip sales increase 1.6% month-to-month

The industrial HVAC market is forecasted to grow by US $6.81 B from 2025 to 2029, with APAC contributing around 41% of that growth—driven by urbanization and industrial expansion.

EINDHOVEN, The Netherlands, January 7, 2025 - NXP Semiconductors N.V. (NASDAQ: NXPI), the worldwide leader in automotive processing and networking, announced today that it has entered into a definitive agreement to acquire TTTech Auto in an all-cash transaction valued at $625 million.

CHIPS Award will Help Strengthen Supply Chain Resilience and is Expected to Create Over 1,000 Manufacturing and Construction Jobs

Facility is expected to host the world’s first 300mm front-end semiconductor manufacturing and advanced packaging research facility

Cutting-Edge Technology Enables Collaborative Design and Research to unleash New Frontier of Innovation for the Semiconductor Industry

MEDTECH startup Lucence has received expanded Medicare approval for its LiquidHallmark cancer test to include the reimbursement for circulating tumour RNA analysis, under the United States’ federal health insurance programme.

This follows the 2023 approval of the cancer test for circulating tumour DNA analysis under Medicare.

The company now stands as the only provider with Medicare coverage for a test that combines both circulating tumour DNA and RNA analyses, Lucence said on Thursday (Jan 2).